Novel immunosuppressive agents in kidney transplantation

摘要: Excellent outcomes have been achieved in the field of renal transplantation. A significant reduction acute rejection has attained at many transplant centers using contemporary immunosuppressive, consisting an induction agent, a calcineurin inhibitor, antiproliferative agent plus or minus corticosteroid. Despite improvements with these regimens, chronic allograft injury and adverse events still persist. The perfect immunosuppressive regimen would limit eliminate inhibitors and/or corticosteroid toxicity while providing enhanced outcomes. Potential to inhibitor class include prolonged release tacrolimus formulation voclosporin, cyclosporine analog. Belatacept shown promise as replace inhibitors. novel, fully-human anti-CD40 monoclonal antibody, ASKP1240, is currently enrolling patients phase 2 trials minimization avoidance regimens. Another future goal immunosuppression effective safe treatment rejection. Novel treatments for antibody mediated bortezomib eculizumab. Several investigational agents are no longer being pursed transplantation including agents, efalizumab alefacept, maintenance sotrastaurin tofacitinib. purpose this review consolidate published evidence effectiveness safety recipients.